Tagraxofusp Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm With Loss of CD123 Expression: Case and Review of Literature

Background: Tagraxofusp, a CD123 based targeted immunotherapy, was recently approved to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) with excellent response. Also, a subset of BPDCN showed resistance to tagraxofusp. These resistant cases continue to express CD123, which forms the basis of the continued utility of tagraxofusp in newer combination chemotherapies to overcome resistance in BPDCN. Case presentation: Herein we report a case of an elderly male with BPDCN that initially achieved complete remission on primary treatment with tagraxofusp. However, BPDCN relapsed after 1.5 years while on treatment with loss of CD123 expression. Conclusions: This case highlights a potential limitation of current and upcoming tagraxofusp based therapies, at least in a subset of refractory BPDCN. We believe our report will serve as a sentinel to incite future investigations involving alternate resistance mechanisms in BDPCN.


Background:
Targeted therapy has found a new success story through the growing utility of tagraxofusp, a CD123 directed antineoplastic drug. Tagraxofusp (SL-401, DT388IL-3, or tagraxofusp-erzs) internalizes into target cells by binding surface IL-3 receptor-alpha (CD123) and inhibits cellular protein translocation by ADP ribosylation of eukaryotic elongation factor-2 (eEF-2), subsequently causing cell death [1,2]. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive neoplasm derived from the precursor plasmacytoid dendritic cells characterized by the expression of CD303, CD123, CD56 CD4, and TCL1, [3][4][5]. This ubiquitous expression of CD123 makes BPDCN a prime target for treatment with tagraxofusp, as described in a pilot study by Frankel et al.[6]. Subsequently, a multicenter clinical trial for single-agent tagraxofusp showed complete response in 72% cases on initial therapy and an overall response rate of 67% in relapsed refractory patients of BPDCN [7]. In response, the FDA approved tagraxofusp for the management of BPDCN in December 2018. The utility of this promising new drug extends potentially to other neoplasms strongly expressing CD123, including acute myeloid leukemia (AML) [8], hairy cell leukemia [9], and B-lymphoblastic leukemia [10]. The effectiveness of this drug has also been tested in tyrosine kinase-resistant CML [11].
Tagraxofusp resistance has been observed in a subset of cases in early clinical trials [6, 7] and published reports [12,13]. The resistance to single-agent tagraxofusp is attributed to a block in Diphtheria Toxin (DT) effect due to the alteration of the diphthamide pathway. Of interest, refractory BPDCN continues to express CD123 both during and after treatment, highlighting intact IL3-CD123 mediated bindinginternalization of tagraxofusp in the target cell [14,15]. Utilizing the persistent targeting ability of tagraxofusp in CD123 expressing refractory BPDCN, combination therapy of tagraxofusp with hypomethylating agents (like azacitidine) has shown promising results to reverse DT resistance [14].
Herein, we report the rst case (to the best of our knowledge) of tagraxofusp refractory BPDCN with no identi able expression of CD123 on relapse. Our case may indicate a new pathway of resistance with the potentially limited utility of the upcoming CD123 dependent multidrug regimen in refractory BPDCN.

Case Presentation:
A 78-year-old male has a long history of Crohn's disease (post ileectomy, not requiring continuous medications) and hypothyroidism (on levothyroxine). Seven years ago, the patient was diagnosed with a plasma cell neoplasm with monoclonal IgG lambda (1.0g/dL) protein, hemoglobin (Hb) 10.9g/dL, mean corpuscular volume (MCV) 102 , White blood cells (WBC) 2000/µL (absolute neutrophil count (ANC): 700/µL; absolute lymphocyte count (ALC) 1200k/µL), and platelets 172X10 3 /µL, The bone marrow at the time showed involvement by 20% clonal plasma cells with large clusters, with no bone lesions on the radiological survey. Karyotype showed 46,XY [20]. And the patient was treated with lenalidomide and dexamethasone followed by autologous stem cell transplant to achieve remission. After six years, the patient developed a new-onset skin rash. A bone marrow biopsy at this time showed extensive (~ 85%) involvement by blast-like population positive for CD4 (dim), CD56 (heterogenous) ( ow cytometry), CD123, and TCL1 (immunohistochemistry (IHC)) and was diagnosed as BPDCN. The karyotype was normal 46,XY [20], and targeted molecular studies showed mutations in TET2 and ZRSR2. Treatment with tagraxofusp (12 µg/kg once daily for ve days in a 21-day cycle) resulted in the resolution of bone marrow involvement and skin lesions. The patient stayed in remission for 1.5 years followed by sudden onset leukocytosis (WBC 16.4k/uL, Hg:7.8g/dL; MCV118; and Platelets 80k/uL). Physical examination was unremarkable with no skin rash, lymphadenopathy, or organomegaly. Peripheral blood smear revealed large immature appearing cells with a round to folded nucleus, vesicular chromatin, scant cytoplasm with rare cytoplasmic projections. Flow cytometry showed immature cells to be positive for dim CD45 expression and low side scatter, located in the "blast gate," and expressed CD56, CD117 (small subset), HLA-DR, CD7, and CD38, but negative for CD123 (clone: Beckman Coulter™ SSDCLY107D2), CD34, myeloid/monocytic markers (myeloperoxidase (MPO), CD33, CD13, CD41, CD14, CD64) and lymphoid markers (surface and cytoplasmic CD3, and CD19) (Fig. 1). The bone marrow biopsy was 80-90% cellular and extensively involved by sheets of large immature cells (

Discussion:
We report a relapse of BPDCN while on treatment with single-agent tagraxofusp (12uL/kg), with no identi able expression of CD123 as evaluated by two different methods (IHC and ow cytometry) and two different antibody clones. BPDCN is frequently diagnosed based on the co-expression of CD123, TCL1, CD56, and CD4 on neoplastic cells in the absence of other lineage-de ning markers like MPO, CD19, and CD3. Although the absence of CD123 expression in our case challenges a diagnosis of BPDCN and raises close differential, especially with acute undifferentiated leukemia. The clinical history, characteristic morphology, and co-expression of CD56 and TCL1 (strong and nuclear) in the absence of markers de ning other lineages con rmed the diagnosis [16,17]. Also, ow cytometric ndings were concordant on both peripheral blood and bone marrow specimen collected two days apart. The lack of identi able expression of CD123 may potentially be explained by downregulation or internalization of receptor components. Also, a potential block of CD123 (IL3 receptor) by tagraxofusp causing a failure of identi cation is theoretically possible. However, it has not yet been reported even during therapy.
Tagraxofusp, recombinant IL3 + truncated (catalytic and translocation domain of DT), acts via a two-step process. First involves IL3 mediated binding/ internalization to target the CD123 [IL-3(r)-alpha] positive tumor cells. The second step involves the cytoplasmic localization of the truncated DT to cause ADP phosphorylation of the histidine 715 on eEF2, causing a block of protein synthesis and eventually cell death. The resistance to tagraxofusp was evident in a subset of cases from early clinical trials. While no acquired somatic mutations were identi ed by whole exome sequencing, the resistance correlated with an acquired downregulation of DPH1 (diphthamide biosynthesis 1) in the tagraxofusp resistant clones [14,15]. DPH1, the rst enzyme in a series of at least seven member enzymes, converts histidine715 on eEF2 to diphthamide [18], resulting in loss of direct target of DT mediated inhibition of translocation, i.e., DT resistance.
Togami et al. elegantly describe the persistent expression of CD123 during and after treatment in BPDCN and AML to be associated with a survival advantage. Also, they highlight relative dependency on CD123 for survival in AML cell lines compared to other disease types, based on a gene-knockout experiment on cell lines from the genome-wide RNA interference screening [19] [20]. Thus, the absence of CD123 expression in myeloid lineage cancers, AML (and BPDCN) would be disadvantageous for the survival of the CD123 negative clone, especially during treatment.
Similarly, BPDCN resistance to tagraxofusp demonstrated by other authors has shown persistent surface expression of CD123. In their series of pediatric BPDCN, Sun et al. described tagraxofusp resistance in one case with multiple relapses with CD123 positive neoplastic cells after two rounds of therapy. Two other cases showed good initial response followed by disease progression. One of these (tested) cases was positive for CD123 at disease progression [12]. More recently, Samhouri et al. described a case of an elderly male with BPDCN (involving skin) and concomitant myelodysplastic syndrome with ring sideroblasts (bone marrow) as refractory to low dose tagraxofusp (5µg/kg; due to drug intolerance) and eventually achieved remission after switching to combination venetoclax and azacytidine [13].
Multidrug therapy has been used to overcome single-agent tagraxofusp resistance. Togami et al. con rmed the regulation of DPH1 by reversible promoter CpG DNA methylation, as seen previously [21], in AML and BPDCN. They showed reversal of DT-based resistance by synergistic cytotoxicity of CD123 mediated targeting by tagraxofusp with the hypomethylating effect of azacitidine in patient-derived xenografts models. Secondly, tagraxofusp resistance in both AML and BPDCN was associated with increased overall apoptotic priming and showed increased dependence on BCL-2 and or BCL-XL [15].
Such results have led to multiple trials evaluating combinations of tagraxofusp, azacitidine, and venetoclax (BCL-2 inhibitor) in BPDCN {NCT03113643, NCT03485547, and NCT04216524} Along similar lines, success stories of combination tagraxofusp and azacitidine in the management of relapsed BPDCN [22] highlight bright scope for speci c multidrug management in BPDCN.

Conclusion:
Herein, we describe an intriguing rst example of tagraxofusp refractory BPDCN that relapsed while on full-dose single-agent tagraxofusp with loss of CD123 expression as evaluated by different methods.
Although additional studies are required to understand the mechanism behind the absence of identi able expression of CD123. Our case may highlight a potential limitation of targeting CD123 in a subset of refractory BPDCN. We believe our report will be of signi cance to the current scienti c literature on CD123 based targeted immunotherapy and should induce a formal investigation into alternative mechanisms of BPDCN resistance and its resolution. Dot plots for ow cytometric analysis of peripheral blood at relapse of BPDCN. The population of BPDCN cells is highlighted in red color and involves the "blast gate" with low side scatter and dim CD45 expression (Fig.1A). Relapsed BPDCN is negative for CD123 (Fig.1B) and shows CD56 expression (Fig.1C). BPDCN cells show no expression of CD11b or CD64 (Fig.1D).

Figure 2
Bone marrow evaluation at relapse of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Fig.2A shows bone marrow aspirate (Wright-Giemsa Fuccillo stain modi cation; original magni cation X1000) with frequent BPDCN cells characterized by large immature cells with round to folded nuclear contours, and high nuclear to cytoplasmic ratio and rare with cytoplasmic projections. Fig. 2B shows bone marrow clot section (Hematoxylin-Eosin stain; original magni cation X200) with a hypercellular marrow showing extensive involvement by sheets of atypical large mononuclear immature BPDCN cells. Figure